WEP CLINICAL HAS PARTNERED WITH PHARMING GROUP TO SUPPLY LENIOLISIB POST-FDA APPROVAL THROUGH A POST-APPROVAL NAMED PATIENT PROGRAM Read More 20th June 2023
WEP CLINICAL PARTNERS WITH SOLASIA PHARMA K.K. TO LAUNCH DARVIAS NAMED PATIENT PROGRAM Read More 20th March 2023
WEP CLINICAL PARTNERS WITH Y-MABS THERAPEUTICS TO PROVIDE DANYELZA THROUGH A NAMED PATIENT ACCESS PROGRAM IN EUROPE Read More 16th February 2023
WEP CLINICAL HAS PARTNERED WITH TAIMED BIOLOGICS TO LAUNCH A TROGARZO NAMED PATIENT PROGRAM Read More 6th February 2023
WEP CLINICAL ANNOUNCES PARTNERSHIP WITH PHARMING GROUP FOR EXPANDED ACCESS PROGRAM FOR LENIOLISIB Read More 8th June 2022
WEP CLINICAL PARTNERS WITH SELLAS LIFE SCIENCES GROUP TO LAUNCH EXPANDED ACCESS PROGRAM FOR GALINPEPIMUT-S Read More 4th May 2022
